LongeVC has invested in psychedelics startup Freedom Biosciences which is pioneering the use of ketamine and other compounds in next-generation treatments.
LongeVC has added Freedom Biosciences to its portfolio of companies which it states are deploying AI to find new treatments for chronic illnesses, developing SaaS tools to accelerate life-changing medical research and more.
Freedom Biosciences was founded by Yale University professor Dr John Krystal and PsyMed Ventures co-founder Dina Burkitbayeva, and is developing next-generation therapeutics to treat mental health conditions.
The company launched from stealth in 2022 and is backed by MBX Capital, Village Global and PsyMed Ventures, among others, including Marat Kichikov.
Dr Krystal’s clinical work and research at Yale were instrumental in developing Janssen’s Spravato Esketamine spray, which received FDA approval for patients with treatment-resistant depression in 2019.
Freedom Biosciences co-founder and CEO Dina Burkitbayeva said: “Clinical research has already shown how powerful psychedelics can be in managing difficult-to-treat mental health conditions.
“We are harnessing their power to offer new, more effective medicines to patients in need.”
Garri Zmudze, co-founder and managing partner of LongeVC, which focuses on Focusing on seed and early-stage investment and states that its mission is to bring to market breakthrough biotech that will change lives and transform the nature of our health, added: “Better mental health is essential for healthy longevity and should be treated as an integral part of the life extension agenda.
“By tackling pressing psychological conditions, we strive to support lives that are mentally and physically healthier.”
